Related Experiment Video

Updated: Jun 9, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Targeting CDK2 to combat drug resistance in cancer therapy

Sara Kasirzadeh1, Jimma Likisa Lenjisa1, Shudong Wang1

  • 1Drug Discovery & Development, Clinical & Health Sciences, University of South Australia, Adelaide, 5000, Australia.

Future Oncology (London, England)
|October 29, 2024
PubMed

Insights

Drug resistance is a major challenge in cancer. This review shows Cyclin-dependent Kinase 2 (CDK2) drives resistance to various cancer treatments, making it a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Drug resistance is a significant barrier to effective cancer treatment, contributing to high mortality rates.
  • Understanding the molecular mechanisms underlying cancer drug resistance is crucial for developing improved therapeutic strategies.

Purpose of the Study:

  • To review the critical role of Cyclin-dependent Kinase 2 (CDK2) in both intrinsic and acquired drug resistance in various cancers.
  • To evaluate CDK2 as a potential therapeutic target for overcoming treatment resistance.

Main Methods:

  • Literature review focusing on studies investigating CDK2 and its associated proteins in cancer resistance.
  • Analysis of the link between Cyclin E (partner of CDK2) upregulation and patient prognosis.
  • Examination of genetic alterations, such as CCNE1/CCNE2 amplifications, and their association with resistance to diverse therapies.

Main Results:

  • CDK2 plays a pivotal role in intrinsic and acquired resistance across multiple cancer types.
  • Upregulation of Cyclin E, which complexes with CDK2, correlates with poor prognosis and treatment resistance.
  • Amplifications of CCNE1/CCNE2 genes are frequently observed in cancers resistant to targeted therapies, immunotherapy, endocrine therapies, and conventional chemo/radiotherapy.

Conclusions:

  • CDK2 is implicated in key resistance mechanisms, highlighting its significance in cancer treatment failure.
  • Targeting CDK2 presents a promising avenue for developing novel therapeutic strategies to overcome drug resistance.
  • Further investigation into CDK2's role can lead to improved treatment outcomes and reduced cancer mortality.
Keywords:
CDK2 inhibitorchemotherapycyclin Ecyclin-dependent kinasesdrug resistancetargeted therapy

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.2K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K